Study Overview
Sex: All
Age: 18 Years / N/A
Study Documents
Study Protocol and Statistical Analysis PlanStudy Overview
Sex: All
Age: 18 Years / N/A
Completed
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia
Beigene Study ID
ClinicalTrials.gov ID
EudraCT Number
China Drug Trials ID
Sex: All
Age: 18 Years / N/A
Sex: All
Age: 18 Years / N/A